TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07021742: BioHealx® Anal Fistula Device Post Market Surveillance Study

Sponsor: Signum Surgical USA Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 50 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,095,600

Rescue Site Savings

+$730,400

Unlock Full NCT07021742 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07021742 Rescue Dossier →